AI Revolutionizing Healthcare and Biotechnology
Artificial intelligence (AI) has long been tied to major tech companies, but it’s now establishing itself as a vital asset in various sectors. This is especially true in healthcare and biotech, where AI is reshaping product discovery, development, and delivery. Take Eli Lilly (LLY), for example—this global pharmaceutical player focuses on developing medications for conditions like diabetes, obesity, and various cancers.
Currently, LLY’s market value stands at about $901.8 billion. However, it has experienced a 12% drop in value so far this year, while the S&P 500 index has only declined by 4%.
AI Driving Drug Discovery
The journey to bring a new drug to market can take over ten years in the biotech field. AI offers the prospect of accelerating this process by identifying promising drug candidates faster, optimizing clinical trials, and lowering the rates of failure. Eli Lilly is making significant investments in this area. Recently, the company announced a partnership with Nvidia (NVDA) to collaborate on an AI lab that merges advanced computing with scientific know-how to speed up drug discovery.
As a result of these AI initiatives, Lilly currently has 36 active Phase 3 programs and has launched 14 new late-stage clinical trials, marking one of the most extensive clinical pipelines in its history. Notably, the company is focusing on obesity and metabolic treatments like orforglipron and retatortide, which have shown promising results in the late stages of their trials. Lilly has committed more than $55 billion towards expanding manufacturing since 2020, boosting production capacity in new facilities across the U.S. and Europe. By 2025, it aims to produce 1.8 times more incretin than in 2024. Additionally, Lilly plans to acquire Centessa Pharmaceuticals (CNTA) for about $6.3 billion, adding a promising lineup of orexin receptor 2 (OX2R) agonists aimed at treating sleep-wake disorders, including narcolepsy.
On April 1, LLY shares increased by 3.7% following an FDA announcement that approved orforglipron, a daily oral treatment for obesity. This treatment aims to make obesity care more accessible, with costs starting at $25 per month for those with insurance and $149 for self-pay patients. The convenience of taking Foundayo without the need for food or water restrictions may lead to higher adoption rates. This move fortifies Lilly’s standing in a quickly expanding obesity treatment market. In 2025, the company reported an impressive $65.2 billion in sales, representing a 45% year-over-year growth, thanks to strong demand and volume increases in key markets like the U.S., Europe, Japan, and China. Lilly also achieved a solid gross margin of 83.2%, with adjusted net income soaring by 96% to $22.95 per share.
Looking ahead, projected revenue for 2026 ranges from $80 billion to $83 billion, signaling approximately 25% growth at the midpoint. Additionally, earnings per share are anticipated to rise by 49%, reaching between $33.50 and $35. In healthcare, AI is not just enhancing drug discovery and patient outcomes; it’s also creating entirely new markets. Companies like Eli Lilly illustrate that by merging AI with experience, financial resources, and execution, they can gain substantial competitive edges. Analysts predict Lilly’s profits will increase by about 43.2% in 2026 and 21.3% in 2027.
Wall Street’s Perspective on LLY Stock
Eli Lilly holds a “Strong Buy” rating across Wall Street. Out of 30 analysts assessing the stock, 23 classify it as a “strong buy,” three as a “moderate buy,” and four suggest a “hold.” The average price target stands at $1,238.46, hinting at a potential 30% increase from current valuations. Additionally, the highest estimated market price of $1,500 indicates the stock could rise as much as 57% in the coming year.
